Abstract:The Kirsten rat sarcoma viral oncoprotein homolog (KRAS) is currently a primary focus of oncologists and translational scientists, driven by exciting results with KRAS-targeted therapies for non-small cell lung cancer (NSCLC) patients. While KRAS mutations continue to drive high cancer diagnosis and death, researchers have developed unique strategies to target KRAS variations. Having been investigated over the past 40 years and considered "undruggable" due to the lack of pharmacological binding pockets, recent breakthroughs and accelerated FDA approval of the first covalent inhibitors targeting KRAS G12C , have largely sparked further drug development. Small molecule development has targeted the previously identified primary location alterations such as G12, G13, Q61, and expanded to address the emerging secondary mutations and acquired resistance. Of interest, the non-covalent KRAS G12D targeting inhibitor MRTX-1133 has shown promising results in humanized pancreatic cancer mouse models and is seemingly making its way from bench to bedside. While this manuscript was under review a novel class of first covalent inhibitors specific for G12D was published, These so-called malolactones can crosslink both GDP and GTP bound forms of G12D. Inhibition of the latter state suppressed downstream signaling and cancer cell proliferation in vitro and in mouse xenografts. Moreover, a non-covalent pan-KRAS inhibitor, BI-2865, reduced tumor proliferation in cell lines and mouse models. Finally, the next generation of KRAS mutant-specific and pan-RAS tri-complex inhibitors have revolutionized RAS drug discovery. This review will give a structural biology perspective on the current generation of KRAS inhibitors through the lens of emerging secondary mutations and acquired resistance.

Eliminating oncogenic RAS: back to the future at the drawing board

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

Targeting KRAS in cancer

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C

KRAS mutation: from undruggable to druggable in cancer

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

The current state of the art and future trends in RAS-targeted cancer therapies

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

RAS-targeted therapies: is the undruggable drugged?

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Drugging KRAS: current perspectives and state-of-art review

Inhibitors of the GTPase KRASG12C in Cancer: a Patent Review (2019-2021).

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives